Depressive disorders arise from a combination of genetic and environmental risk factors. Epigenetic disruption provides a plausible mechanism through which gene-environment interactions lead to depression. Large-scale, epigenome-wide studies on depression are missing, hampering the identification of potentially modifiable biomarkers.
RESULTS
The discovery cohorts consisted of 7948 individuals (4104 [51.6%] women) with a mean (SD) age of 65.4 (5.8) years. The replication cohort consisted of 3308 individuals (2456 [74.2%] women) with a mean (SD) age of 60.3 (6.4) years. The EWAS identified methylation of 3 CpG sites to be significantly associated with increased depressive symptoms: cg04987734 (P =1.57×10 −08
; n = 11 256; CDC42BPB gene), cg12325605 (P =5.24×10 −09 ; n = 11 256; ARHGEF3 gene), and an intergenic CpG site cg14023999 (P =5.99×10 −08 ; n = 11 256; chromosome = 15q26.1). The predicted expression of the CDC42BPB gene in the brain (basal ganglia) (effect, 0.14; P =2.7×10
−03 ) and of ARHGEF3 in fibroblasts (effect, −0.48; P =9 .8×10
−04
) was associated with major depression.
CONCLUSIONS AND RELEVANCE This study identifies 3 methylated sites associated with depressive symptoms. All 3 findings point toward axon guidance as the common disrupted pathway in depression. The findings provide new insights into the molecular mechanisms underlying the complex pathophysiology of depression. Further research is warranted to determine the utility of these findings as biomarkers of depression and evaluate any potential role in the pathophysiology of depression and their downstream clinical effects.
D epression is one of the most common mental health disorders that is projected to play a leading role in disease burden by 2030. 1 In later life, depression is associated with disability, increased mortality, dementia, and poor outcomes from physical illness. 2 Furthermore, more people older than 65 years commit suicide than in any other age group, and most have major depression. 3 Limited understanding of the molecular mechanisms underlying depression is a hindrance in the development of innovative treatment, prognostic markers, and prevention strategies. Studying depression is challenging because it is a heterogeneous disorder with a multifactorial etiology. 4 This heterogeneity increases with age as the incidence of chronic diseases and disability rises. The contribution of genetics to the risk of depression is moderate, with heritability estimates ranging from 40% to 50% 5 and modest (18%) in the elderly. 6 Genome-wide association studies (GWAS) have identified numerous rare and common genetic variants associated with depression and related traits. [7] [8] [9] [10] However, genetic variation alone does not completely explain an individual's risk for developing depression. Among environmental factors, adverse life events and stress are major risk factors for depression.
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Converging evidence from animal and human studies suggests that psychosocial stressors trigger depression onset by inducing elevations in proinflammatory cytokine levels. 12 These psychosocial stressors are also known to influence epigenetic mechanisms, such as DNA methylation, 13 that can drive sustained changes in gene expression. 14 The high contribution of environmental factors to depression in the elderly makes DNA methylation a candidate mechanism for studies of the molecular basis of late-life depression. DNA methylation may be global or tissue specific. 15 Tissues likely to be involved in complex psychiatric disorders, such as brain, are not directly accessible from living patients. The use of postmortem brain tissue to study DNA methylation is a possible solution, although obtaining a sufficient sample size is challenging. 16 To study differential DNA methylation associated with mental health symptoms on a large scale, peripheral tissues, such as blood, constitute a useful proxy for detecting trans-tissue changes and the most appropriate tissue for biomarkers. 16, 17 Moderate correlation has been demonstrated between blood and brain tissues at nontissue-specific regulatory regions across the methylome. 18 To date, several studies have assessed the correlation between depression and DNA methylation. 19, 20 However, these studies have been limited to a small number of DNA methylation sites (CpG sites) and/or small samples. For instance, the largest published epigenome-wide association study (EWAS) assessed brain DNA methylation in 76 persons who died during a depressive episode and 45 controls. 21 Moreover, these studies compared depressed cases with healthy controls. Depression represents an arbitrarily selected extreme of the continuum of varying severity and duration, 22 whereas a broad phenotype approach can be more representative for the general population. A large study consisting of 252 503 individuals from 68 countries showed that subthreshold depressive disorders produce significant decrements in health and do not qualitatively differ from full-blown episodes of depression. 23 A meta-analysis in individuals older than 55 years found 2 to 3 times higher prevalence of subthreshold depressive symptoms than major depression. 24 Use of rating scales has therefore been recommended for the assessment of depressive problems in the elderly. 2 In the present investigation, we performed an EWAS of depressive symptoms using whole-blood samples of 7948 individuals of European ethnicity from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. We replicated our findings in 3308 individuals of African American and European ancestry. Finally, we used publicly available expression quantitative methylation loci and expression quantitative loci databases to identify the downstream effects of the associated methylation loci.
Methods

Study Population
The study sample for the discovery analysis included a total of 7948 participants of European ancestry from 9 populationbased cohorts of the CHARGE consortium ( Table 1) : Cardiovascular Health Study, 25 Framingham Heart Study, 27 Helsinki Birth Cohort Study, 29 Cooperative Health Research in the later for the replication phase of the study. 40 Detailed information for each cohort is provided in the eAppendix in the Supplement.
Depressive Symptoms Assessment
Depressive symptoms were measured using self-reported questionnaires or structured interviews performed by a trained researcher, psychologist, or psychiatrist at the same time when blood samples were obtained for DNA methylation quantification (Table 1) . 26 
DNA Methylation Sample and Measurement
In all cohorts, DNA was extracted from whole blood and methylation levels were assessed (Illumina-Infinium Human Methylation 450K BeadChip; Illumina Inc) using standard manufacturer's protocols. The 450K array includes more than 450 000 CpGs and is enriched for genic regions, covering 99% of all genes. DNA methylation data preprocessing, including quality control and normalization, was conducted per cohort using study-specific methods. In all cohorts, DNA methylation levels were quantified as β values, which range from 0 to 1 and indicate the proportion of DNA strands in a sample methylated at a specific CpG. Detailed information about cohort-specific DNA extraction, bisulfite conversion, DNA methylation profiling, normalization, and quality control is described in the eAppendix in the Supplement.
Statistical Analysis Epigenome-wide Association Analysis
In all cohorts, the association between depressive symptoms and CpG sites was assessed using linear regression analysis.
In the regression analysis, DNA methylation β value at each 44 (assessed at the time of blood sampling for methylation), methylation batch effects, white blood cell composition (imputed or directly measured), principal components estimated using genome-wide genotype data to control for population stratification, and familial relationships when required. Cohort-specific details of these analyses are provided in the eAppendix in the Supplement. Furthermore, sensitivity analysis was performed by adjusting the initial model for antidepressant medication use at the time of sample collection.
To pool the results from independent studies, we performed sample size-weighted meta-analysis in METAL. 49 We chose the sample size-weighted method because of the differences in the measurement scales of depressive symptoms across studies. A drawback of using the sample size-weighted method is that no pooled-effect estimates are generated. To obtain pooled-effect estimates, we additionally performed inverse variance-weighted meta-analysis for the top sites in cohorts that used the CES-D 20-item scale for the assessment of depressive symptoms. Any CpG sites missing in more than 3 of the participating cohorts were removed. In total, 484 516 probes were tested for association, giving a Bonferronicorrected genome-wide significance threshold of 0.05/ 484516=1.03×10 −7 . All CpG sites suggestive of association
) were tested for association in the independent replication cohorts using the same model as used in the discovery EWAS. Finally, a sample size-weighted meta-analysis was performed for all cohorts included in the discovery and replication phases in METAL. To evaluate the contribution of each study to the association results, we generated posterior probabilities of the effects in each study (M-values) using the METASOFT package.
50 M-value and forest plots for z scores were generated using custom-made scripts in R. For annotating CpG sites, we used the annotation provided by Illumina and the University of California Santa Cruz UCSC database (GRCh37/hg19).
Gene Expression Analyses
To evaluate the downstream effects of the 3 identified CpG sites in blood, we used the BIOS database to search for expressionquantitative methylation. 51 To evaluate whether the expression of the genes that either harbored or whose expression was associated with the significant CpG sites was associated with major depression (also smoking and inflammation to check specificity), we used the MetaXcan, version 0.50 package.
52,53
MetaXcan associates the expression of the genes with the phenotype by integrating functional data generated by largescale efforts, such as genotype-tissue expression (GTEx) with that of the GWAS. MetaXcan is trained on transcriptome models in 44 human tissues from GTEx and is able to estimate their tissue-specific effect on phenotypes from GWAS. We used the GTEx-V6p-HapMap-2016-09-08 database and the publicly available GWAS data sets of major depression, 54 C-reactive protein, 55 and smoking, 56 which represent important potential confounders in the present study.
Causal Inference Analysis
To help infer causal associations, we studied the cis singlenucleotide polymorphisms (SNPs) identified by the BIOS consortium 51 as instrumental variables for the CpG sites as proposed by Relton and Davey Smith. 57 We checked the association of these cis-SNPs with depression, smoking, and inflammation in the published GWAS of these traits. Similarly, we checked whether the SNPs associated with inflammation (C-reactive protein levels), 55 smoking, 56 and depression 7 were associated with the identified CpG sites using the BIOS consortium database. We chose smoking and inflammation because these are highly correlated with both depression and DNA methylation and thus could influence the association between depression and DNA methylation.
Results
The mean (SD) age in the discovery cohorts ranged from 52. 
Epigenome-wide Association Analysis
In the meta-analysis of depressive symptoms of European ancestry, we identified 1 CpG site on chromosome 14q32.32 (cg04987734, CDC42BPB [OMIM 614062]; P =4. 93×10 −08 ; n = 7948) that passed the Bonferroni threshold for significance ( Table 2 ; eFigure 1 in the Supplement). Furthermore, suggestive association was observed at 19 additional CpG sites ( Table 2) . Adjusting for antidepressive medication use did not meaningfully change the results (eTable 1 in the Supplement). No inflation in the test statistic was observed (λ = 1.03) (eFigure 2 in the Supplement). We tested all 20 CpG sites for association in the replication sample. The top CpG site from the discovery (cg04987734) showed nominal association (P < .05; n = 3308) with depressive symptoms in the validation data set ( Table 2 ). In addition, significant association of a CpG site (cg12325605; P =9.17×10 −05
; n = 3308) ( Table 2) annotated to the ARHGEF3 [OMIM 612115]g enewi thdepr essive symptoms was observed in the replication sample.
Meta-analysis of discovery and replication cohorts showed a significant association of both cg04987734 (P =1.57×10 −08 ; n = 11 256) and cg12325605 (P =5.24×10 −09 ; n = 11 256) with depressive symptoms (Table 2, Figure 1 and Figure 2 ). An additional intergenic CpG site (cg14023999; P =5. 99×10 −08 ; n = 11 256) at chromosome 15q26.1 locus showed genomewide significant association with depressive symptoms (eTable 2, eFigure 3, and eFigure 4 in the Supplement). The independent contributions of each cohort to the association signals of the 3 CpGs are depicted in eFigure 5 in the Supplement and also provided in eTable 3 in the Supplement. For all 3 CpG sites, the association signals were not driven by a single cohort, but appeared to be linearly related to the sample size, suggesting stronger association in larger studies (eFigure 5 in the Supplement). Pooled-effect estimates in cohorts that used the CES-D scale suggest that a 1-unit increase in the CES-D score increases methylation by 0.05% at cg04987734, 0.04% at cg12325605, and 0.03% at cg14023999.
Gene Expression Analyses
There was a significant association between cg04987734 and increased expression of the CDC42BPB gene (false discovery rate, P =7 . 7×10 −04 ; n = 2101) and cg14023999 was significantly associated with decreased expression of SEMA4B (OMIM 617029) (false discovery rate, P =4.7×10 −03
; n = 2101) in blood (eTable 4 in the Supplement). No significantly associated gene expression probes were identified for cg12325605 in blood. Furthermore, the predicted expression of the CDC42BPB gene in the brain (basal ganglia) (effect, 0.14; P =2. 7×10 −03 ) and of ARHGEF3 in fibroblasts (effect, −0.48; P =9.8×10 −04 ) was associated with major depression (eTable 5 in the Supplement). No association was observed with either smoking or inflammation.
Blood and Brain Correlation
We checked the correlation between methylation in blood and various brain regions at the 3 identified sites using a webbased tool (BECon
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) and a blood-brain DNA methylation comparison tool (http://epigenetics.essex.ac.uk/bloodbrain/). BECon showed correlation between blood and brain DNA methylation, for example, methylation at cg04987734 in the CDC42BPB gene was highly correlated (r = 0.81) between blood and the Brodmann area 7 that spans the medial and lateral walls of the parietal cortex (eFigure 6 in the Supplement). Methylation at the other 2 sites was negatively correlated with methylation in the Brodmann area 10 that spans anterior prefrontal cortex (cg12325605, r = −0.39; cg14023999, r =−0 .42), suggesting strong but reverse methylation patterns in blood and brain (eFigure 7 and eFigure 8 in the Supplement). However, the blood-brain DNA methylation comparison tool that contrasts DNA methylation between blood and prefrontal cortex, entorhinal cortex, superior temporal gyrus, and cerebellum showed only modest correlations. For instance, methylation in blood at cg04987734 showed the strongest correlation with methylation in superior temporal gyrus (r =0 .18; http://epigenetics.essex.ac.uk/bloodbrain/?probenameg= cg04987734), while methylation in blood at cg12325605 (http: //epigenetics.essex.ac.uk/bloodbrain/?probenameg= cg12325605) and cg14023999 (http://epigenetics.essex.ac.uk /bloodbrain/?probenameg=cg14023999) showed the strongest correlation with methylation in cerebellum (r = 0.16; r =0 .19, respectively). Nevertheless, the findings from the 2 databases suggest some degree of correlation between methylation in blood and methylation in brain for the 3 identified CpG sites.
Causal Inference
In the BIOS database we identified 2 cis-SNPs for cg04987734, 4 cis-SNPs for cg12325605 (eTable 6 in the Supplement), and none for cg14023999. We took the most significant cis-SNP as the proxy for the CpG sites if available. For cg04987734, we used rs751837 as a proxy and for cg12325605 we used rs3821412 as a proxy (top cis-SNP rs9880418 was not available in the GWAS of depression, smoking, or inflammation). There was suggestive association between rs751837 and major depression (P = .07; albeit in the opposite direction) (eTable 7 in the Supplement); rs3821412 was not associated with any of the 3 tested phenotypes. None of the SNPs associated with depression, inflammation, or smoking was associated with any of the 3 CpG sites. 
Discussion
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On the top graph, the x-axis depicts the position in base pair (bp) (hg19) for the entire CDC42BPB gene region. The y-axis indicates the strength of association in terms of negative logarithm of the association P value. Each circle represents a CpG site. Red dashed line within the graph indicates the genome-wide significance threshold. The regulatory information and correlation matrix of other CpG sites in the region with the top hit are shown below the x-axis. Color intensity marks the strength of the correlation and color indicates the direction of the correlation. The figure was made using web-based plotting tool and R-based package CoMET (http://epigen.kcl.ac.uk/comet/). Ensembl is a genome database resource (http://ensemblgenomes.org/). SNP indicates singlenucleotide polymorphism; UCSC, University of California Santa Cruz.
genes associated with major depression in brain and fibroblasts, respectively. CDC42BPB (CDC42 binding protein kinase beta) encodes a member of the serine/threonine protein kinase family, which is a downstream effector of CDC42 and plays a role in the regulation of cytoskeleton reorganization, cell migration, and regulation of neurite outgrowth 58 ; CDC42BPB is highly expressed in the brain (https://www.proteinatlas.org/ENSG00000198752-CDC42BPB/tissue). Hypermethylation of cg04987734 has been associated with increased expression of CDC42BPB in blood. 51 Methylation levels at this CpG site (cg04987734) were also previously associated with C-reactive protein levels in blood 43 and smoking. 44 In our study, however, we adjusted for smoking in the regression model; therefore, the association cg06521544  cg10147507  cg26259546  cg11741902  cg00478127  cg24634060  cg02031326  cg11167446  cg07563047  cg25799109  cg24007644  cg13745870  cg20749059  cg04563996  cg10913077  cg08976117  cg18109369  cg04389058  cg05400732  cg00836272  cg11229273  cg16087328  cg19142341  cg05722035  cg16451527  cg26311262  cg12704098  cg24830876  cg19513744  cg17537252  cg20509080  cg09641077  cg20138711  cg01016119  cg21077300  cg18482892  cg20888995  cg07391913  cg14633892  cg15012214  cg12325605  cg26319282  cg18562759  cg00883019  cg12835118  cg13912849  cg06521544  cg10147507  cg26259546  cg11741902  cg00478127  cg24634060  cg02031326  cg11167446  cg07563047  cg25799109  cg24007644  cg13745870  cg20749059  cg04563996  cg10913077  cg08976117  cg18109369  cg04389058  cg05400732  cg00836272  cg11229273  cg16087328  cg19142341  cg05722035  cg16451527  cg26311262  cg12704098  cg24830876  cg19513744  cg17537252  cg20509080  cg09641077  cg20138711  cg01016119  cg21077300  cg18482892  cg20888995  cg07391913  cg14633892  cg15012214  cg12325605  cg26319282  cg18562759  cg00883019  cg12835118 between depression and DNA methylation of this CpG site may be independent of smoking habits. Also, our causal inference analyses provide no support for the possibility that smoking or inflammation explained the observed association with depressive symptoms or that the predicted expression of the gene showed an association with smoking or inflammation. The ARHGEF3 gene encodes for rho guanine nucleotide exchange factor 3 protein. The gene is highly expressed (https: //www.proteinatlas.org/ENSG00000163947-ARHGEF3 /tissue) in adrenal glands, brain, and uterus. Both ARHGEF3 and CDC42BPB are coexpressed with several members of the rho subfamily (RHOA, RHOB, and RHOC) (eFigure 9 and eFigure 10 in the Supplement) of the rho guanosine triphosphatase family that also includes CDC42. 59 The 
Strengths and Limitations
To our knowledge, this is the largest EWAS of depressive symptoms reported to date. Our major strength is the sample size that enabled detection of a replicable epigenome-wide significant locus, which suggests that in blood, DNA methylation signatures associated with depression may be subtle and will require large samples to be detected. However, this study has several limitations. First, the study was using peripheral blood tissue for DNA methylation profiling, as DNA methylation is known to be tissue specific. 71 Although peripheral blood is not considered to be the most relevant tissue for the pathophysiology of depression, some sites show correlated methylation profiles between tissues. 15 75 This is likely to be especially true for a trait such as depressive symptoms, for which the severity and duration of illness can be highly heterogeneous. 22 Genome-wide studies of depressive traits, using quantitative endophenotypes, have been suggested to improve statistical power. 22 However, the use of different phenotypic measures by different cohorts means that there may be some loss of statistical power owing to the heterogeneity in the phenotype assessment. Nevertheless, the top 3 sites in our study were robustly associated with depressive symptoms independent of the depressive symptom measure used. Fourth, although we adjusted for potential confounders, the possibility of residual confounding cannot be excluded. Antidepressant medication indicates treated depression but itself may result in epigenetic modifications involved in depression pathophysiology.
76 Antidepressants can thus mediate or confound the association between DNA methylation and depression. However, in sensitivity analysis additionally adjusted for antidepressant medication, our results did not change. Fifth, most cohorts included in this EWAS were composed of elderly persons. The cause of depression is more heterogeneous in elderly people than in younger people and often hidden behind somatic symptoms, either because of somatization of the disorder or because of accentuation of symptoms of concomitant illness. 77 This heterogeneity may affect the generalizability of the results to younger populations. Finally, we made an attempt to disentangle cause and consequence using SNPs associated with the identified CpG sites and depression, inflammation, and smoking as instrumental variables. The results did not support a causative role, yet the association of the predicted gene expression of CDC42BPB in brain and ARHGEF3 in fibroblasts with major depression does suggest a possible causal role of the regulatory effects of these genes.
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Conclusions
To our knowledge, we report the first EWAS of depressive symptoms. We identified and replicated association of 2 methylation sites in the genome with depressive symptoms. A third site was identified in the meta-analysis of discovery and replication cohorts, which requires further replication. All 3 findings point toward axon guidance as the common disrupted pathway in depression (http://www.genome.jp/kegg/pathway /hsa/hsa04360.html). Our findings provide new insights into the molecular mechanisms underlying the complex pathophysiology of depression. 
eAppendix. Study Specific Details Cardiovascular Health Study Cohort
Description. The CHS is a population-based cohort study of risk factors for coronary heart disease and stroke in adults ≥65 years conducted across four field centers. (1) The original predominantly European ancestry cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare eligibility lists. CHS was approved by institutional review committees at each field center and individuals in the present analysis had available DNA and gave informed consent including consent to use of genetic information for the study of cardiovascular disease.
DNA methylation sample, measurement, normalization and quality control. DNA methylation was measured on a randomly selected subset of 323 European descent participants from study year. The samples were randomly selected among participants without presence of coronary heart disease, congestive heart failure, peripheral vascular disease, valvular heart disease, stroke or transient ischemic attack at study baseline or lack of available DNA at study year 5. Methylation measurements were performed at the Institute for Translational Genomics and Population Sciences at the Harbor-UCLA Medical Center Institute for Translational Genomics and Population Sciences using the Infinium HumanMethylation450 BeadChip (Illumina Inc, San Diego, CA). Quality control was performed in in the minfi R package.(2-4) (version 1.12.0, http://www.bioconductor.org/packages/release/bioc/html/minfi.html). Samples with low median intensities of below 10.5 (log2) across the methylated and unmethylated channels, samples with a proportion of probes falling detection of greater than 0.5%, samples with QC probes falling greater than 3 standard deviation from the mean, sex check mismatches, or failed concordance with prior genotyping were removed. Methylation values were normalized using the SWAN quantile normalization method. (3) Since white blood cell proportions were not directly measured in CHS they were estimated from the methylation data using the Houseman method.(5) All association analyses were performed in R using linear mixed models with DNA methylation beta values as the outcome. Analyses adjusted for age, gender, current smoking status and antidepressant medication. Additionally chip, chip row and column were adjusted for as random effects. CHS was approved by institutional review committees at each field center and individuals in the present analysis had available DNA and gave informed consent including consent to use of genetic information for the study of cardiovascular disease. The DNA methylation dataset from CHS can be requested at https://chs-nhlbi.org/node/6222.
Depressive symptoms assessment. Depressive symptoms were assessed during an in-person interview using the Center for Epidemiology Studies-Depression (CES-D) 10 item scale.
Covariates. Smoking and medication were assessed during an in-person interview, at the time of blood assessment for methylation. Smoking was assessed with a standard questionnaire, medications were assessed by an inventory of all prescription medication containers used in the 2 weeks prior to the interview.
Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Framingham Heart Study (FHS)
Description. The Framingham Heart Study (FHS) is a population-based, prospective study. In 1948, the Original cohort of 5209 individuals were recruited from Framingham, MA. (6) The offspring cohort was recruited in 1971, including 5,124 offspring and spouses of offspring of the FHS Original cohort. (7) Offspring participants underwent examinations every four years (except eight years between the first and the second examinations). (7) DNA methylation sample, measurement, normalization and quality control. Peripheral whole blood samples were collected from these participants at the eighth examination (2005) (2006) (2007) (2008) . Buffy coat fractions were obtained and genomic DNA was extracted using the Gentra Puregene DNA extraction kit (Qiagen, Venlo, Netherlands). Depressive symptoms assessment. Depressive symptoms were evaluated using the Center for Epidemiologic Studies Depression Scale (CES-D)(9), a 20-item scale consisting of 4 factors: depressive affect, somatic complaints, positive affect, and interpersonal relations (1). This 20-item, self-report scale, designed for use in community studies, has been validated in studies similar to the Framingham Heart Study . The CES-D scale was self-administered in the offspring cohort. Scores on the CES-D range from 0 to 60, with higher scores reflecting greater depressive symptoms.
Covariates. At each examination, participants underwent a medical history, physical examination, and fasting blood sample collection. Clinical covariates were assessed at the same examination cycle as the blood sample obtained for DNA methylation. Details of the examination assessments have been previously described (10) and are available in detail at http://www.framinghamheartstudy.org/fhs-forresearchers/. Self-reported cigarette smoking status was divided into three categories. Current smokers were defined as those who have smoked at least one cigarette a day within 12 months prior to the blood draw, former smokers were defined as those who had ever smoked at least one cigarette a day, but had stopped at least 12 months prior to the blood draw, and never smokers reported never having smoked. Medication use was ascertained by physicians by detailed review of participant medication lists, and participants were asked to bring medication bottles to the clinic examination for review.
Analysis.
We followed the analysis plan. Two models were performed. In order to reduce the batch effects, we analyzed the DNA methylation in each lab: residuals were obtained by regressing a CpG against the batch effects (plate, row and col numbers) and lab-specific principle components that were related to the outcome. Residuals from two labs were put together and then regressed against the CESD, adjusting for covariates and family structure. Plate ID and family structures were treated as random effects in linear mixed models. To study the effects of early separation from parents on methylome, we selected 83 evacuated men with data on age at and length of evacuation and of father's occupational status and 83 non-evacuated controls matched for sex, birth year and father's occupational status in childhood for the methylation typing. In this study, the analyses are based on 62 evacuated men and 60 non-evacuated controls with full data on CESD depressive symptoms, covariates, and methylation profiles. For this group the mean age was 63.5 years (SD = 2.8).
Helsinki Birth Cohort Study (HBCS)
DNA methylation sample, measurement, normalization and quality control. DNA methylation analysis was performed at the Genetics Core of the Wellcome Trust Clinical Research Facility (Edinburgh, UK). Bisulphite conversion of 500 ng input DNA was carried out using the EZ DNA Methylation Kit (Zymo Research, Freiburg, Germany). Four microlitres of bisulphite-converted DNA was processed using the Infinium HD Assay for Methylation. This was performed using the Illumina Methylation 450 k beadchip and Infinium chemistry (Illumina, Inc., San Diego, CA, USA). Each sample was interrogated on the arrays against 485 000 methylation sites. The arrays were imaged on the Illumina HiScan platform and genotypes were called automatically using GenomeStudio Analysis software version 2011.1. Quality control pipeline was set up using the R-package minfi, including intensity read outs, normalization, cell type composition estimation, -and M-value calculation. We excluded samples with low intensity (badSampleCutoff < 10.6) or deviant beta distribution based on visual inspection (n = 5). We did not detect any gender discrepancy. Data were normalized with functional normalization (FunNorm). Of the probes, we excluded those with detection p-value > 0.01 in > 50 % of samples(11), non-autosomal and non-specific binding probes as well as probes with SNPs in the interval for which the Illumina probe is designed to hybridize and if they were located close (10bp from query site) to a SNP which had a minor allele frequency of ≥0.05. Probes located in the X and Y chromosome were also excluded. This yielded a total number of probes of 424,844. Batch effects were identified by inspecting the association of principal 0.01 in > 1 % samples, were filtered out. questions that correspond with criterion based-symptoms associated with depression, and they could score from 0-60. The screening for depressive symptoms was performed during the home interview by trained research assistants.
Covariates. Age, sex, current smoking status and antidepressant medication were measured using standard cohort specific protocols at the time DNA samples were collected. During this interview participants reported on their smoking behavior (current, former and never) and psychotropic medication use. Moreover, to confirm the self-reported use of antidepressants prescription, the Anatomical Therapeutical Chemical-Code(22) data was collected from pharmacies linked records. Exposure to an antidepressant was defined as current user and non-user of any antidepressant as described in detail elsewhere. (22) White blood cells counts (monocytes, granulocytes and lymphocytes) were measured immediately at the research center using a standard hematology analyzer (Beckman Coulter, Pasadena, CA, USA).
Analysis. An epigenome-wide linear regression was performed per DNA methylation probe with CESD depression score adjusting for covariates in R. Model 1 was adjusted for age, sex, smoking status, batch effects and cell composition, while Model 2 was additionally adjusted for antidepressant medication use.
Infinium HumanMethylation450 BeadChip (Illumina Inc., San Diego, California), according to the manufacturers protocol. Samples were assigned to slides such that gender was counter-balanced. Methylation array processing was carried out at the Wellcome Trust Clinical Research Facility, The University of Edinburgh. Raw intensity (.idat) files were read into R using the minfi package(2), which was used to perform initial quality control assessments by assessing signal from the array's internal control probes. All samples were deemed to have performed well based on the output of the control probes. Probe and sample filtering was performed using the pfilter function in wateRmelon.(16) Probes were excluded if they had a detection p-value ≥ 0.05 in more than 5% samples (n = 1000) or had a beadcount of less than 3 in more than 5% samples (n = 466). All samples satisfied an inclusion criterion of having no more than 5% probes with a detection p-value ≥ 0.01. The final dataset comprised 484145 probes measured in 227 individuals. The raw data ( -values) were normalised using the dasen function in wateRmelon. (16) The DNA methylation data from the Generation Scotland (GS) data is available on request to e-mail: access@generationscotland.org. GS has Research Tissue Bank status, and the GS Access Committee reviews applications to ensure that they comply with legal requirements, ethics and patient consent.
Assessment of depression.
Diagnoses of depression were established by trained researchers who administered the screening questions of the Structured Clinical Interview for DSM-IV (SCID)(24) to all GS:SFHS participants. Those who screened positive were subsequently assessed using the mood disorder sub-sections of the SCID. Major depressive disorder (MDD) was diagnosed in those meeting the criteria for MDD whose symptoms could not be better explained by bipolar disorder, a general medical condition or substance abuse.
Covariates. The following variables were included as covariates: sex, age, current smoking status; family; estimated blood cell counts; batch (methylation slide ID); and methylation-based principal components. Antidepressant usage was additionally included as a covariate in a sensitivity analysis carried out to assess the contribution of antidepressant use to depression-associated methylation differences. Smoking status was determined by self-report at the time of blood sample collection and was recorded as a binary variable (current smokers vs. non-smokers (never smokers and ex-smokers)). Antidepressant usage was also determined by self-report at the time of blood sample collection. No data on antidepressant usage was available for seven individuals. Estimated proportions of six blood cell types (monocytes, granulocytes, CD4+ T-cells, CD8+ T-cells, Bcells and natural killer cells) were obtained using the estimateCellCounts function in minfi. (5, 25) In order to avoid collinearity, one cell type, natural killer cells, was excluded from the analyses. Methylation-based principal components were identified using prcomp without scaling. PCA was performed on the matrix of residualised -values obtained after residualising for the other covariates included in the model used to identify differentially methylated positions (principal components were estimated separately for model 1 and model 2). Principal components that individually accounted for at least 1% of the variance were included as covariates. For both models, this resulted in the inclusion of the first six principal components. As our sample comprised related individuals (100 discordant sib pairs and 27 singletons), it was necessary to account for relatedness. This was achieved using the duplicateCorrelation function in limma (26, 27) to fit family as a random effect.
Analysis. Differences in DNA methylation associated with the diagnosis of depression were detected using the following linear mixed effects models (family was treated as a random effect and all other covariates as fixed effects), implemented in limma (27) : The WHI-EMPC study population is a stratified, random sample of 2,200 WHI CT participants who were examined between 1993 and 2001; had available buffy coat, core analytes, electrocardiograms, and ambient concentrations of PM; but were not taking anti-arrhythmic medications at the time.
As such, WHI-EMPC is representative of the larger, multiethnic WHI CT population from which it was sampled: n = 68,132 participants aged 50-79 years who were randomized to hormone therapy, calcium / vitamin D supplementation, and / or dietary modification in 40 U.S. clinical centers at the baseline exam (1993-1998) and re-examined in the fasting state one, three, six, and nine years later.(36) During participant visits, data on age, race/ethnicity, smoking status, depressive symptoms, and antidepressant medication use were obtained. Current analyses were in European Americans and involved information collected at the first visit with available DNA methylation (DNAm) data.
DNA Methylation. Genome-wide DNAm at CpG sites was measured using the Illumina 450K Infinium Methylation BeadChip, quantitatively represented by beta (the percentage of methylated cytosines over the sum of methylated and unmethylated cytosines), and quality controlled using the following filters: detection p-values > 0.01 in > 10% of samples, detection p-values > 0.01 in > 1% of probes, yielding values of beta at 484,220 sites. DNAm data was normalized using BMIQ (30) , then stage-and plate-adjusted using ComBat. (12) Modeled epigenome-wide associations also adjusted for principal components for ancestral admixture, cell subtype proportions (CD8-T, CD4-T, B cell, natural killer, monocyte, and granulocyte) (5) The right panels depict the posterior probability of effect in each study (M value) against the negative logarithm of the p value for that study. Red dots suggest that the study has an effect (m value > 0.9), green dots suggest that the study's effect is uncertain (0.1 < m value < 0.9), while blue dots (not observed in our case) would suggest that the study has no effect (m value < 0.1).
